Clinical trial
A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD III
NCT04990388 is registered in ClinicalTrials.gov with Ultragenyx Pharmaceutical Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD III
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- October 18, 2021
- Completion date
- March 20, 2023
- Enrollment
- 9 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.